Introduction
Strongyloides, Trypanosoma cruzi and West Nile virus (WNV) are important pathogens that have been transmitted via deceased organ donors. Given the potential for transmission to result from living donation, the Organ Procurement and Transplantation Network (OPTN) mandated, effective February 2013, that transplant centers must test for evidence of infection with Strongyloides, T. cruzi and WNV if the potential live donor is from an endemic area (1) . However, the policy does not provide specific guidance regarding implementation, including appropriate selection of donors for testing, optimal testing modalities and timing. Therefore, the American Society of Transplantation Infectious Diseases Community of Practice, in conjunction with disease-specific experts, has developed this viewpoint to provide guidance related to testing of live donors for these infections with a focus on the identification of at-risk populations, advantages and limitations of specific testing algorithms, and interpretation of results.
Strongyloides
Infection with Strongyloides stercoralis occurs when the larvae penetrate the skin of persons walking in soil contaminated with feces and typically occurs in people from rural agricultural areas, especially if poor sanitation exists. Autoinfection is an important source of prolonged carriage and adult worms can live for up to 5 years, allowing for ongoing infection even when the donor is no longer living in the endemic area. Consequently, individuals may remain chronically infected and able to transmit infection throughout their lives via organ donation. Individuals infected with Strongyloides are often asymptomatic; symptomatic infection occurs more commonly in immunocompromised hosts. Manifestations may be variable and involve the gastrointestinal and/or pulmonary tracts, sepsis syndromes, gram-negative bloodstream infections, and/or meningitis (especially with gram-negative organisms). The most severe manifestation is hyperinfection syndrome (2) .
The precise prevalence of chronic infection is unknown. The disease occurs throughout the world and infection rates are highest in tropical or subtropical regions, exceeding 80% in some locations. In the United States, rates as high as 3.8% have been measured in Appalachia and southeastern states (3) . The last community-based survey was conducted in 1982, and current rates are unknown.
Which living donor candidates should be screened for Strongyloides? Strongyloidiasis typically occurs only in the setting of specific environmental exposures; thus, screening all potential live donors is not indicated. Screening is justified for the following potential organ donors:
Persons who were born in or lived in tropical or subtropical countries where sanitation conditions are substandard. This includes candidates with prior military service in endemic areas. Strongyloidiasis has occurred in most countries with the exception of Canada, Japan and Northern Europe. Persons with unexplained eosinophilia and travel to endemic area. Those born in the United States who have significant exposure to soil in Appalachia or the southeastern United States. Persons reporting a prior history of Strongyloides infection.
How should donor candidates be screened for Strongyloides? Strongyloides IgG antibody testing is readily available in many reference labs (Table 1) . Currently, these ELISA assays (which correlate with antibody to filariform larvae) are not specifically approved by the Food and Drug Administration (FDA) for donor testing. Test sensitivities vary and false-negative results have occurred, including in early infection and immunocompromised hosts. Indirect immunofluorescence assays have improved sensitivity; however, they are generally only available through research laboratories. There is no standard commercially available confirmatory testing for antibody positive specimens; falsepositive tests are uncommon. Individuals with a history of treatment for Strongyloides infection may have persistent antibody; consequently, those donors should undergo further evaluation by an expert in infectious diseases. Serology is the preferred screening test for Strongyloides infection, as the sensitivity of stool testing is limited and multiple stool screening tests may be negative in asymptomatic chronic infection. Fecal examination for Strongyloides larvae may sometimes identify additional infected individuals who are newly infected and can be requested at the time of the initial evaluation. Because the methodology used to identify Strongyloides differs from that for routine ova and parasite examinations, it is important to specify the organism when ordering the test. Multiple stool specimens should be obtained to increase the yield; the optimal number is unknown but reports note that seven consecutive daily specimens may increase the sensitivity to nearly 100% (4) . Given that transplant candidates may share similar epidemiological risk factors for Strongyloides infection, potential recipients with similar geographic exposures should also be considered for screening and treatment should be administered if found to be positive.
Eosinophilia is commonly seen in patients with active Strongyloides infection. Thus, those individuals with potential environmental exposures and unexplained eosinophilia should undergo serological testing and fecal examination for Strongyloides. However, since eosinophilia is not universally noted in patients with chronic strongyloidiasis, it should not be used as the only determinant for which individuals are screened with serologic testing. The optimal timing of live donor testing has not been established. However, unless the donor will resume residence in an environment where new exposures are likely, it is reasonable to test at the time of donor identification. If the donor cannot be treated prior to donation or receives only a single course of treatment, then the recipient should be treated with the same regimen as outlined for the donor (considering two courses of two doses of ivermectin separated by 2 weeks as the most conservative approach) as soon as possible after the transplant has occurred (7). There are no significant drug interactions and the medication is typically well tolerated with no requirement for dose adjustment based on either renal or hepatic function. All recipients of organs from donors with Strongyloides infection should be monitored clinically; no additional serological or microbiological studies are indicated in the absence of symptoms. If recipients develop signs and symptoms consistent with Strongyloides infection or eosinophilia, expert consultation should be obtained. Serological diagnosis is unreliable in patients receiving immunosuppressive medications; therefore, appropriate samples (e.g. stool, respiratory samples) should be obtained for direct examination for Strongyloides larvae. Because eosinophilia is not always present, its absence cannot exclude the diagnosis. Recipients with posttransplant Strongyloides infection should be treated with ivermectin; the dose and duration may vary with the specific clinical syndrome and expert consultation should be solicited (7).
Chagas Disease
T. cruzi infection (the agent of Chagas disease) is most commonly transmitted through contact with infected triatomine ''kissing'' bugs, but transmission has also been reported through blood transfusion, organ transplantation and from mother to infant. Residents of poorly constructed housing where these insects reside are at greatest risk of acquiring infection. Endemic areas include many parts of Mexico and most of Central and South America (see Table 2 ). However, due to recent immigration it is estimated that more than 300 000 T. cruzi infected people are living in the United States. In the United States, 32 organ transplant recipients from 14 T. cruzi seropositive donors have been investigated: 2 of 15 (13%) kidney recipients had donor-derived infection (8) . A transmission rate of 18.7% was observed in a case series from Argentina of T. cruzi seropositive kidney donors and T. cruzi seronegative recipients (9) . No live donor-derived T. cruzi infection has been reported in the United States but this has been described in Mexico and South America (8, 9) . Clinical manifestations of donor-derived T. cruzi infection can include fever, malaise, anorexia, hepatosplenomegaly and acute myocarditis with a mean time to diagnosis of infection of 8 weeks (range 3-29 weeks) (8) .
Which living donor candidates should be screened for Chagas disease? T. cruzi can remain latent in humans for decades and be transmitted by organ donation with severe consequences to the recipient. Therefore, screening potentially infected living donors is appropriate. Individuals reporting only brief visits to endemic areas or residence confined to urban areas are considered lower risk for T. cruzi infection and may not need to be screened; however, these criteria have not been fully evaluated. Donors who should be screened include:
Those who were born in or lived in an endemic region in Mexico, Central or South America (see Table 2 ). How should the recipients of T. cruzi positive donor organs be managed posttransplant? Following transplant, monitoring of recipients of kidneys from T. cruzi positive organ donors should be coordinated by local infectious disease experts and incorporate testing at a reference lab (such as the Centers for Disease Control and Prevention [CDC]). Serologic conversion may not occur due to posttransplant immunosuppressive therapy. Monitoring can be accomplished by PCR testing of blood for T. cruzi DNA and review of peripheral blood for parasitemia weekly for 2 months posttransplant, every 2 weeks for the third month, then monthly afterward for a period to be determined by the specific clinical scenario (10) . An assessment of the organ recipient's net state of immunosuppression should be made in the first months posttransplant, and the monitoring interval adjusted accordingly. PCR testing (currently available only at CDC) is more sensitive than direct parasitologic diagnosis, and may be positive days or weeks prior to the appearance of T. cruzi trypomastigotes in the blood (10) . Indirect methods of parasite diagnosis such as hemoculture may require weeks to several months to obtain results. Additional testing is recommended in the setting of intensified immunosuppression, unexplained febrile illness or infection symptoms, or episodes of suspected graft rejection. The likelihood of late reactivation of donor-derived infection is unknown.
Routine prophylaxis of the recipient of a T. cruzi positive donor organ is not recommended (10) (11) (12) . Treatment with both benznidazole and nifurtimox is frequently complicated by significant side effects and there is no clear treatment end point to indicate when infection is definitively cured. Consequently, even recipients of donors who had been previously treated need to be monitored for posttransplant parasitemia. Because neither benznidazole nor nifurtimox is FDA approved or commercially available in the United States, these medications must be obtained for patients with confirmed T. cruzi infection through an investigational new drug (IND) protocol directly from CDC or independently. For this reason, and because of the expertise of CDC laboratories in expedited testing of high-risk organ recipients, early notification of CDC at the time of transplant is advised. Ideally treatment should be initiated in those with increasing reactivity in serial PCR as seropositivity occurs later (8, 13 
West Nile Virus
WNV is a flavivirus that is transmitted by mosquitoes in an enzootic cycle with birds. In the United States, WNV was first noted in 1999 in the New York City area and has since become endemic in widespread regions of the United States (14) . WNV infection is associated with a range of clinical symptoms ranging from asymptomatic infection to neuroinvasive disease. In the immunocompetent population, neuroinvasive disease occurs in 1 in 150 infected individuals and is manifested by altered mental status, meningitis, encephalitis, flaccid paralysis and occasionally death; these complications are estimated to occur in 1 in 40 transplant recipients infected by mosquito bites (15) . Transmission has also occurred via blood and deceased organ donation with an incidence of neuroinvasive disease ranging between 50% and 75% (16) (17) (18) . Since 2002, donorderived transmission events associated with at least nine donors infecting solid organ transplant recipients have been reported (17) (18) (19) (20) (21) (22) (23) . No transmissions have been reported via live donor transplants thus far.
Which living donors should be screened for WNV?
Because WNV is seasonal throughout the United States, year round screening of potential living donors is unlikely to be cost-effective and may result in increased false-positive results associated with testing low prevalence populations (24) . As false-positive results may result in potential organ loss or unnecessary delays in transplantation, timing of testing is critical. Blood banks in the United States screen year-round for WNV using nucleic acid amplification testing (NAT) which identifies the presence of RNA. Due to limitations in reagent availability, personnel and other logistical issues, blood donors are tested in minipools (minipool-nucleic acid amplification test [MP-NAT]). Once one or more minipools is positive by NAT, the blood bank begins screening individual samples (individual donationnucleic acid amplification test [ID-NAT]) (25) .
One potential strategy for determining when to begin testing potential living donors for WNV would be to follow when regional blood banks start performing ID-NAT screening. This will allow for recognition of the onset of WNV in the donor's region of residence, travel or work locations (26) . This approach requires coordination with blood banks. Further, blood banks vary in their criteria from switching between minipool and individual NAT; there is no national standard for blood banks on this issue. Consequently, while basing testing of living donors on regional blood banking WNV results may be cost-effective and associated with the highest positive predictive value for positive NATs, this approach may be impractical for some transplant centers. Knowledge of epidemiologic data such as the number of clinical cases or presence of positive bird or mosquito pools in the donor's areas of potential exposures as reported by local health departments may be useful to transplant centers assessing WNV risk. It should be noted that nonhuman surveillance activities are variable between jurisdictions. Another potential strategy would be the development of a central notification system that could alert transplant centers regarding regional WNV activity.
A second option is to test during a defined period of time that reflects the peak of WNV infection in most of the United States (typically May 1 to November 1). This may be simpler for centers to adopt. In addition, this reduces the likelihood of communication error between laboratories and blood banks. The major disadvantage with this method is that potential donors will be tested despite the absence of circulating WNV in their locales, thereby increasing the likelihood of false-positive test results.
Any potential donor with a recent febrile illness should be screened by local infectious diseases expertise prior to donation. This screening may include West Nile testing as appropriate.
During mosquito season, prospective live donors should be counseled to use personal protective measures against mosquito bites such as insect repellents and avoidance of outside activities between dusk to dawn. These practices are meant to mitigate the risk of acquiring WNV between diagnostic testing and organ donation.
How should live donors be tested? For laboratory screening, live donors should be screened by WNV NAT within 7-14 days of donation. There are currently two FDA-licensed donor screening NAT assays utilized by screening laboratories to detect the presence of infectious WNV virus (Table 4 ). The Procleix 1 WNV Assay (Gen-probe; Novartis Diagnostics, Basel, Switzerland) is based on transcription-mediated amplification, a NAT, which tests up to 16 specimens in the MP-NAT with a specificity of 99.95% and ID-NAT specificity of 99.89% (27,28). The Cobas TaqScreen MPX test (Roche Molecular Diagnostics, Branchburg, NJ) utilizes reverse transcription PCR (RT-PCR) to test up to six specimens with an MP-NAT specificity of 100% and ID-NAT specificity of 99.98% (29, 30) (Table 5 ). Interpretation of the results can be based on the positive predictive value in each case, such as the prevalence of WNV in the community where the donor resides or has traveled.
The use of serologic testing offers an additional potential strategy to screen potential living donors for WNV but poses significant limitations in its performance and interpretation. WNV antibody testing has been done to establish the presence of past infection. This testing involves (1) IgM, which develops within 2-3 days of resolution of viremia, but may persist for >500 days (31), and (2) IgG, which is identified within 2-3 days of IgM production and persists for at least 5 years (32, 33) . It is important to note that serologic tests against WNV are not FDA licensed for the screening of donors. However, a potential role for IgM antibody testing is raised by the fact that two of the nine deceased organ donors who However, further management of a positive NAT test in live donors is unclear because of limited data. One strategy for donor testing is provided in Figure 1 . It is reasonable to repeat NAT testing in this situation; the time to repeat and number of repeat samples may vary depending on the Posttransplant management of recipients of a WNV-positive organ donor At this time, there is no effective treatment for WNV. Consequently, donors with active WNV should be deferred.
In the event of inadvertent transplantation from a WNV infected donor, immunosuppression should be minimized and hyperimmune globulin can be considered (35) . Hyperimmune globulin may be available on a compassionate use basis from Omrix and would likely require an IND; however, the presence of antibody to WNV in US-derived immune globulin has been reported (19, (36) (37) (38) . Recipients may be monitored with serial NAT testing to determine the presence of infection. In the event of a positive NAT result, consultation with local infectious diseases experts is recommended, as well as reporting to transplant centers and public health authorities.
Conclusions
Identifying live donors with potentially transmissible infections should enhance the safety of transplantation, a key objective of the OPTN in mandating testing for WNV, T. cruzi and Strongyloides in this setting. Given that these are uncommon infections in the United States, typically occurring in individuals with specific epidemiologic risk factors, broad testing of all donors throughout the year and in all locales may not be cost-efficient and, in some cases, may unnecessarily eliminate donors or delay transplantation due to false-positive results. In all cases, live donors should also be notified of their positive results. Identifying at-risk donors for targeted testing is critical for efficient utilization of live donors. Banking serum may be a useful tool for confirming donor-derived infection with Strongyloides, T. cruzi and WNV.
